Eliquis Lawsuit | Side Effects: Internal Bleeding
Side Effects: gastrointestinal bleeding, brain bleeds, blood clots, heart attack, stroke, Severe hemorrhages, Severe internal bleeding, death | Blood Thinner Lawsuits, Internal Bleeding Lawsuits | Eliquis Lawsuits | Eliquis Side-Effects Lawsuit
Eliquis Lawsuit Information: Eliquis is a new generation blood thinner prescribed to reduce the risk of stroke among patients with atrial fibrillation not caused by a heart valve problem. Eliquis is part of a class of drugs called New Oral Anticoagulants that were developed to replace warfarin (Coumadin, Jantoven), the oldest blood thinner on the market. While Eliquis has been promoted as a superior alternative to warfarin, Eliquis can cause serious internal bleeding that can require hospitalization. Eliquis also does not have a specific antidote for reversing its anti-clotting effects when uncontrollable bleeding occurs. When bleeding occurs wth warfarin, vitamin K is used as an antidote.
Men and women who have been prescribed Eliquis and have suffered injuries are filing lawsuits over the medication’s side effects. According to Eliquis lawsuits and Eliquis prescribing information, some of the adverse reactions to the drug include:
- Internal bleeding
- Allergic reactions
- Skin rash
- Bruising or bleeding more easily
- Increased risk of bleeding when taken at the same time as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin or other blood thinners
- Death
You or a loved one may be entitled to compensation if you have been harmed by Eliquis. The Eliquis Lawsuit attorneys at Southern Med Law are investigating Eliquis bleeding side-effects lawsuit claims from men and women who have suffered serious and fatal internal bleeding injuries. To speak to one of the firm’s Eliquis Lawsuit Lawyers, please call 205-547-5525 or visit www.southernmedlaw.com for more information.
Eliquis Lawsuits due to serious bleeding side effect
The Eliquis side-effects lawsuits allege that plaintiffs have suffered serious bleeding episodes and Bristol-Myers Squibb did not conduct sufficient testing of Eliquis. The complaints also contend that the company failed to adequately warn that the blood thinner does not have a reversal agent to counteract bleeding. In February 2017, the U.S. Judicial Panel on Multidistrict Litigation centralized all federal Eliquis lawsuits in the Southern District of New York. The cases will now undergo coordinated pretrial proceedings.
(Eliquis Lawsuit Case No. In Re: Eliquis (Apixaban) Products Liability Litigation – MDL No.2754)
[ http://www.jpml.uscourts.gov/sites/jpml/files/MDL-2754-Initial_Transfer-01-17.pdf ]
Eliquis ARISTOTLE Study
FDA approval of Eliquis was based in part on clinical trials known as ARISTOTLE (Apixaban for Reduction in Stroke and Other Thrombotic Events in Atrial Fibrillation), a multinational, double-blind study in patients with nonvalvular atrial fibrillation. ARISTOTLE compared apixaban to warfarin. According to Bristol-Myers Squibb, the study’s results showed apixaban was superior to warfarin in preventing stroke or systolic embolism and was also associated with less bleeding and lower mortality than warfarin. However, Eliquis lawsuits contend Bristol-Myers Squibb committed fraud during the trial by concealing side effects which occurred in test users, including a death that was not reported. The FDA sent letters to Bristol-Myers Squibb regarding these and other concerns that had to be addressed prior to Eliquis’ approval.
[ http://www.acc.org/latest-in-cardiology/clinical-trials/2013/07/19/12/07/aristotle ]
FDA-Approved Uses For Eliquis
Eliquis (apixaban) received approval from the U.S. Food and Drug Administration (FDA) in 2012. ELIQUIS is an oral Factor Xa inhibitor anticoagulant. Eliquis is used to reduce the risk of stroke and systemic embolism in patients with atrial fibrillation not caused by a heart valve problem. Eliquis also treats deep vein thrombosis (blood clots in the veins of the legs) and pulmonary embolism (blood clots in the lungs) and reduce the risk of clots occurring again. Eliquis’ prescribing information includes a warning that discontinuing the blood thinner places patients at an increased risk of thrombotic events.
Eliquis is manufactured and marketed by Bristol-Myers Squibb Company and Pfizer Inc., which have seen skyrocketing sales of their blockbuster drug. Eliquis generated $774 million in revenue in 2014 and jumped to $1.8 billion in 2015. Eliquis lawsuits state that sales of the blood thinner were driven by the companies’ marketing claims that Eliquis is easier to use than warfarin.
[pharmacompass.com/radio-compass-blog/top-drugs-by-sales-revenue-in-2015-who-sold-the-biggest-blockbuster-drugs]
About Southern Med Law And Filing An Eliquis Bleeding Side-Effect Lawsuit
Led by Dr. François Blaudeau, Southern Med Law has worked hard to develop a strong reputation for aggressively and effectively advocating for people who have been injured by dangerous and defective drugs. If you or a loved one experienced life-threatening bleeding complications from blood thinners, please contact the Firm today to learn more about your legal rights. You can arrange for a free, no-obligation Eliquis Bleeding Side-Effect Lawsuit review by filling out our online form, or by calling the office directly at 205-547-5525.